Why the study?
Does donor-recipient HLA matching improve survival, reduce rejection, or prevent death from coronary artery disease in cardiac transplant recipients?
Does donor-recipient HLA matching improve survival, reduce rejection, or prevent death from coronary artery disease in cardiac transplant recipients?
Donor-recipient HLA matching in heart transplant recipients does not significantly improve survival but is associated with fewer rejection episodes.
Answers are grounded in this paper and cite their sources.
Does not support HLA matching for survival benefit in heart transplant allocation; leaves open prospective trials on rejection reduction.
Review of 448 cyclosporine-treated heart transplant recipients was undertaken to examine the relationship of donor-recipient HLA compatibility to patient survival, rejection, and death from coronary artery disease (CAD). Pre-Tx crossmatching and panel-reactive antibody (PRA) were correlated to survival as well. Overall patient survivals were 78%, 70%, and 65% at 1,3, and 5 years post-Tx, respectively. Matching of donor-recipient HLA did not improve outcome in that 1,3, and 5 years survivals for well-matched (< or = 2 A, B, or 0-1 DR mismatches [MMs]) vs. poorly matched (> 2 A, B, or 2 DR MMs) recipients were comparable and not significantly different. Well-matched recipients, however, experienced significantly fewer rejections (1.06 +/- 1.2 vs. 1.96 +/- 1.0, P < 0.01 for < or = 2 A, BMMs vs. > 2 A, B MMs and 1.1 +/- 0.9 vs. 2.0 +/- 1.1 for 0-1 DR MMs vs. 2 DR MMs, P < 0.01). Moreover, HLA-DR, but not HLA A, B was a significant (P < 0.01) predictor of early rejection (<30 days) in that 65% (165/254) of poorly matched vs. only 40% (95/194) of well-matched HLA-DR recipients experienced early rejections. Interestingly, an inverse relationship was found between HLA A and B MM, but not HLA-DR MM, and death from coronary artery disease in that 17% (19/11) of well matched vs 9% (32/327) of poorly matched patients died from CAD. Pre-Tx PRA did not impact patient survival or rejection. Donor-recipient crossmatching was performed utilizing the NIH and/or antiglobulin (AHG) procedures. No survival differences were observed at 1, 2, and 3 years post-Tx when comparing outcome for the 24 NIH crossmatch (XM)-positive (+) with the 424 NIH-XM-negative displayed a positive AHG recipient antidonor displayed a positive AHG recipient antidonor reactivity. When these 10 AHG-XM (+) sera were treated with dithioerythritol (to inactivate IgM) all 10 converted to a negative reactivity, indicating that a positive crossmatch due to IgM reactivity should not be considered a contraindication to cardiac transplantation. These data also suggest that the reactivity of the 24 NIH-XM(+) sera were most likely due to IgM, and that poorly matched heart recipients may benefit from a more aggressive immunosuppressive regimen to prevent early rejections.
No takes yet. Share an insight, caveat, or question.
Kerman et al. (1994) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: